share_log

TransMedics to Participate in the Morgan Stanley 22nd Annual Global Healthcare Conference

TransMedics to Participate in the Morgan Stanley 22nd Annual Global Healthcare Conference

transmedics将参加摩根士丹利第22届全球医疗健康会议
PR Newswire ·  08/21 16:05

ANDOVER, Mass., Aug. 21, 2024 /PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart, and liver failure, today announced that members of the management team will participate in a fireside chat at the upcoming Morgan Stanley 22nd Annual Global Healthcare Conference at the Marriott Marquis New York. The fireside chat will take place on Wednesday, September 4, 2024, at 1:05 p.m. Eastern Time.

麻省安多弗,2024年8月21日/美通社/ -- 医疗技术公司TransMedics Group, Inc.(“TransMedics”)(纳斯达克:TMDX)正在为患有晚期肺脏、心脏和肝脏衰竭的患者转变器官移植治疗。今天宣布该公司管理团队的成员将参加摩根士丹利第22届年度全球医疗保健大会上的座谈会,该会议将在纽约万豪酒店举行。座谈会将于2024年9月4日星期三下午1:05(东部时间)举行。

Event: Morgan Stanley 22nd Annual Global Healthcare Conference
Date: Wednesday, September 4, 2024
Time: 1:05 p.m. ET

活动:摩根士丹利第22届年度全球医疗保健大会
日期:2024年9月4日星期三
时间:下午1:05(东部时间)

A live and archived webcast of the fireside chat will be available on the "Investors" section of the TransMedics website at . The Company's standard investor presentation is also available through this link.

座谈会的音频和存档将在TransMedics网站的“投资者”页面上提供。该公司的标准投资者介绍也可以通过此链接获得。

About TransMedics Group, Inc.
TransMedics is the world's leader in portable extracorporeal warm perfusion and assessment of donor organs for transplantation. Headquartered in Andover, Massachusetts, the company was founded to address the unmet need for more and better organs for transplantation and has developed technologies to preserve organ quality, assess organ viability prior to transplant, and potentially increase the utilization of donor organs for the treatment of end-stage heart, lung, and liver failure.

关于transmedics group,inc。
transmedics是世界上便携式体外温热灌注和评估供体器官移植的领先者。该公司总部位于美国马萨诸塞州安多弗,旨在解决器官移植的需求问题,开发出了保存器官质量、评估器官移植前的可能性和潜在增加供体器官利用率的技术,用于治疗终末心脏、肺和肝功能衰竭。

Investor Contact:
Brian Johnston
332-895-3222
[email protected]

投资者联系人:
Brian Johnston
332-895-3222
[email protected]

SOURCE TransMedics Group, Inc.

资料来源:transmedics group,inc。

声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    抢沙发